Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
PEMAZYRE save search
Innovent Announces Overall Survival Results of Phase 2 Study of Pemazyre® (pemigatinib) in Chinese Patients with Advanced Cholangiocarcinoma Presented at AACR Annual Meeting 2023
Published: 2023-04-20 (Crawled : 00:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 0.25%
H: 1.26%
C: 0.92%
SNY | News | $45.39 -1.56% -1.58% 4.3M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.23%
H: 0.87%
C: 0.29%
pemazyre meeting chinese results study
Incyte Announces Japanese Approval of Pemazyre® (pemigatinib) for the Treatment of Patients with Myeloid/Lymphoid Neoplasms (MLNs)
Published: 2023-03-27 (Crawled : 09:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.5%
H: 1.19%
C: 0.33%
pemazyre approval treatment
Incyte Announces FDA Approval of Pemazyre® (pemigatinib) as the First and Only Targeted Treatment for Myeloid/Lymphoid Neoplasms (MLNs) with FGFR1 Rearrangement
Published: 2022-08-26 (Crawled : 15:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: -2.06%
pemazyre treatment fda approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma
Published: 2022-04-06 (Crawled : 12:00) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) by the NMPA for the Treatment of Adults with Locally Advanced or Metastatic Cholangiocarcinoma with A FGFR2 Fusion or Rearrangement As Confirmed By A Validated Diagnostic Test That Have Progressed After at Least One Prior Line of Systemic Therapy
Published: 2022-04-06 (Crawled : 05:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: 1.23%
H: 3.54%
C: 3.29%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.47%
H: 2.2%
C: 1.93%
pemazyre treatment test diagnostic approval one therapy
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma
Published: 2022-01-24 (Crawled : 12:30) - biospace.com/
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Hong Kong Market for the Treatment of Adults With Locally Advanced Or Metastatic Cholangiocarcinoma With A FGFR2 Fusion Or Rearrangement That Have Progressed After At Least One Prior Line Of Systemic Therapy
Published: 2022-01-24 (Crawled : 08:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -1.97%
H: 0.5%
C: -0.88%
pemazyre treatment ema ces approval system therapy
Incyte Announces Health Canada Conditional Approval of Pemazyre (pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma
Published: 2021-09-17 (Crawled : 22:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: 0.0%
treatment approval
Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement
Published: 2021-06-22 (Crawled : 01:00) - prnewswire.com
LLY | $745.95 -0.64% -0.81% 1.3M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: 0.26%
H: 0.99%
C: -0.07%
treatment ev approval
Incyte Announces the European Commission Approval of Pemazyre® (pemigatinib) as a Treatment for Adults with Locally Advanced or Metastatic Cholangiocarcinoma with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion or Rearrangement
Published: 2021-03-29 (Crawled : 19:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.48%
H: 1.07%
C: -0.32%
treatment growth approval
Incyte Announces Approval of Pemazyre® (pemigatinib) in Japan for the Treatment of Patients with Unresectable Biliary Tract Cancer (BTC) with a Fibroblast Growth Factor Receptor 2 (FGFR2) Fusion Gene, Worsening After Cancer Chemotherapy
Published: 2021-03-23 (Crawled : 11:00) - biospace.com/
INCY | $52.82 0.19% 0.19% 1.5M
|
Health Technology
|
| O: -0.15%
H: 0.25%
C: -2.08%
treatment therapy cancer growth approval
Gainers vs Losers
| 59% | 41% |
Top 10 Gainers
AGBA | News | $1.03 157.5% 57.94% 120M
|
Finance
ZCMD | $1.45 5.84% 52.1% 2.3M
|
Commercial Services
INVO | $1.52 100.0% 51.13% 5M
|
Health Technology
ISPC | $0.421 97.65% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.5 45.65% 470K
|
OST | $0.509 23.81% 45.26% 90K
|
GDHG | $0.263 21.76% 40.66% 3.1M
|
XPON | News | $3.15 63.21% 37.74% 16M
|
TIRX | $0.8 65.02% 30.74% 58M
|
BNTC | News | $6.82 42.08% 30.64% 3.5M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.